Skip to main navigation
Skip to content
Customer Service: 866-788-9007
PHYSICIAN LOGIN   |   CRF LOGIN   
ORDER TEST
Castle Biosciences, Inc.
  • Company
    • About Us
    • History
    • Executive Management
    • Board of Directors
    • Licenses
    • Careers
    • Contact Us
  • Products
    • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
    • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME
  • Research & Development
    • Our Approach
    • Tests in Development
    • Cutaneous Squamous Cell Carcinoma
    • Suspicious Pigmented Lesions
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Annual Reports
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
    • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Investor Resources
      • Annual Meeting
      • Investor FAQs
      • Investor Contact
      • Email Alerts
  • Scientific Publications
  • Resources
    • Healthcare Professionals
    • Login/Register
    • Order a Test
    • Reimbursement
    • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage
  • August 10, 2020  Castle Biosciences Announces Second Quarter 2020 Results

Annual Reports

Annual Reports

2020 Proxy Statement
April 23, 2020
2020 Proxy Statement 313.7 KB
2019 Annual Report
April 23, 2020
2019 Annual Report 4.7 MB
Latest News
  • Castle Biosciences Announces Second Quarter 2020 Results August 10, 2020
  • Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference August 5, 2020
  • Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020 July 27, 2020
  • Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma July 15, 2020
  • Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma July 9, 2020

Site - Investor Tools

Print Page
Print Page
RSS Feeds
RSS Feeds
Email Alerts
Email Alerts
Investor Contact
Investor Contact
Search
Search
 

Connect with Us

Company

  • About Us
  • History
  • Leadership
    • Executive Management
    • Board of Directors
  • Licenses
  • Careers
  • Contact Us

Products

  • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
  • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME

Research & Development

  • Our Approach
  • Tests in Development
  • Cutaneous Squamous Cell Carcinoma
  • Suspicious Pigmented Lesions

Latest News & Publications

  • Press Releases
  • Scientific Publications
  • Email Alerts

Resources

  • Healthcare Professionals
    • Login/Register
    • Order A Test
    • Reimbursement
  • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage
Copyright © 2020 Castle Biosciences, Inc. | All Rights Reserved
  • Privacy Policy
  • Terms of Use
  • Contact Us
7ads6x98y